

Overview

Useful For

Diagnosis of C3 deficiency

Investigation of a patient with undetectable total complement level

Method Name

Automated Liposome Lysis Assay

NY State Available

Yes

Specimen

Specimen Type

Serum Red

Ordering Guidance

The total complement assay (COM / Complement, Total, Serum) should be used as a screen for suspected complement deficiencies before ordering individual complement component assays. A deficiency of an individual component of the complement cascade will result in an undetectable total complement level.

Specimen Required

**Patient Preparation:** Fasting preferred

**Supplies:** Sarstedt 5 mL Aliquot Tube (T914)

**Collection Container/Tube:** Red top

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 1 mL

Collection Instructions:

- 1. Immediately after specimen collection, place the tube on wet ice.
- 2. Centrifuge and aliquot serum into plastic vial.
- 3. Immediately freeze specimen.

Specimen Minimum Volume

0.5 mL

Reject Due To

|                 |        |
|-----------------|--------|
| Gross hemolysis | OK     |
| Gross lipemia   | Reject |

|               |    |
|---------------|----|
| Gross icterus | OK |
|---------------|----|

Specimen Stability Information

| Specimen Type | Temperature | Time    | Special Container |
|---------------|-------------|---------|-------------------|
| Serum Red     | Frozen      | 14 days |                   |

Clinical & Interpretive

Clinical Information

Complement proteins are components of the innate immune system. There are 3 pathways to complement activation: 1) the classical pathway, 2) the alternative (or properdin) pathway, and 3) the lectin (or mannan-binding lectin) pathway. The classical pathway of the complement system is composed of a series of proteins that are activated in response to the presence of immune complexes. A single IgM molecule or 2 IgG molecules are sufficient to trigger activation of the recognition complex initiated by C1q. The activation process triggers a cascade that includes an amplification loop. The amplification loop is mediated by C3, with cleavage of a series of proteins, and results in 3 main end products: 1) anaphylatoxins that promote inflammation (C3a, C5a), 2) opsonization peptides that are chemotactic for neutrophils (C3b) and facilitate phagocytosis, and 3) the membrane attack complex (MAC), which promotes cell lysis.

The absence of early components (C1-C4) of the complement cascade results in the inability of immune complexes to activate the cascade. Patients with deficiencies of the early complement proteins are unable to clear immune complexes or to generate lytic activity. These patients have increased susceptibility to infections with encapsulated microorganisms. They may also have symptoms that suggest autoimmune disease in which complement deficiency may be an etiologic factor.

C3 is at the entry point for all 3 activation pathways to activate the MAC. C3 deficiency may result in severe and recurrent pneumococcal and neisserial infections. Deficiency is very rare, with less than 30 cases described.

Complement levels can be detected by antigen assays that quantitate the amount of the protein (C3 / Complement C3, Serum). For most of the complement proteins, a small number of cases have been described in which the protein is present but is nonfunctional. These rare cases require a functional assay to detect the deficiency.

Reference Values

21-50 U/mL

Interpretation

Low levels of complement may be due to inherited deficiencies, acquired deficiencies, or due to complement consumption (eg, as a consequence of infectious or autoimmune processes).

Absent C3 levels in the presence of other normal complement values are consistent with a C3 deficiency.

Cautions

Absent (or low) C3 functional levels in the presence of normal C3 antigen levels should be replicated with a new serum specimen to confirm that C3 inactivation did not occur during shipping.

**Clinical Reference**

1. Davis ML, Austin C, Messmer BL, et al: IFCC-standardization pediatric reference intervals for 10 serum proteins using the Beckman Array 360 system. Clin Biochem. 1996;29(5):489-492
2. Gaither TA, Frank MM: Complement. In: Henry JB, ed. Clinical Diagnosis and Management by Laboratory Methods. 17th ed. WB Saunders Company; 1984:879-892
3. O'Neil KM: Complement deficiency. Clin Rev Allergy Immunol. 2000;19:83-108
4. Frank MM: Complement deficiencies. Pediatr Clin North Am. 2000;47(6):1339-1354
5. Brodzski N, Frazer-Abel A, Grumach AS, et al: European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, diagnosis, and management. J Clin Immunol. 2020;40(4):576-591
6. Willrich MAV, Braun KMP, Moyer AM, Jeffrey DH, Frazer-Abel A. Complement testing in the clinical laboratory. Crit Rev Clin Lab Sci. 2021 Nov;58(7):447-478. doi: 10.1080/10408363.2021.1907297

**Performance****Method Description**

C3 complement activity is measured by mixing patient serum with a C3-deficient serum. The lytic activity of the serum mixture is tested against sensitized, labeled liposomes. If lysis occurs, the patient serum must be the source of the C3. The target liposomes are a commercial reagent (WAKO total complement CH50), and the assay is performed on Advia XPT.(Unpublished Mayo method)

**PDF Report**

No

**Day(s) Performed**

Monday through Friday

**Report Available**

1 to 3 days

**Specimen Retention Time**

14 days

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.

- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86161

LOINC® Information

| Test ID | Test Order Name              | Order LOINC® Value |
|---------|------------------------------|--------------------|
| C3FX    | C3 Complement, Functional, S | 87723-3            |

| Result ID | Test Result Name             | Result LOINC® Value |
|-----------|------------------------------|---------------------|
| C3FX      | C3 Complement, Functional, S | 87723-3             |